Kymera Q2 net loss $42.1M, cash $702M; Sanofi expands KT-474 Phase 2

Kymera Therapeutics, Inc.

2024-Q2 EPS reported -$1.26 revenue$35,937,000

Net loss $42.1M in Q2 2024 vs $38.8M in Q2 2023; revenue from Sanofi collaboration $25.7M.
Cash & equivalents $702M as of June 30, 2024; projected runway into first half 2027.
Sanofi plans to expand KT-474 (IRAK4) Phase 2 trials in HS and AD after interim safety/efficacy review.
STAT6 degrader KT-621 Phase 1 on track for H2 2024; TYK2 degrader KT-294 Phase 1 in H1 2025.
KT-253 (MDM2) and KT-333 (STAT3) Phase 1a enrollment completion expected H2 2024 with data presentations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.